Advertisement

Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis

Although well tolerated, simtuzumab monotherapy or with ruxolitinib did not confer clinical benefit or reduce bone marrow fibrosis consistently in patients with myelofibrosis by 24 weeks, a recently published study has shown.

 Oncology Nurse Advisor

click me